1 Title

Can a specific biobehavioral based therapeutic education program lead to changes in pain
perception and brain plasticity biomarkers in chronic pain patients? A study protocol for a
randomized clinical trial.

5

6Trial registration: NCT05623579. Registered on ClinicalsTrials.gov. Ethical committee7registrationnumber:1901202202822.

8

9 Abstract

Background: Chronic pain conditions are complex multifactorial disorders with physical, 10 11 psychological, and environmental factors contributing to their onset and persistence. Among 12 these conditions, the role of brain-derived neurotrophic factor (BDNF) and the impact of a 13 specific therapeutic education (TE) on pain management have emerged as important areas of 14 research. **Objective:** The aim of this study is to investigate the effects of a specific type of 15 therapeutic education on pain levels and BDNF concentrations. Methods: In this single-blind, 16 randomized clinical trial, patients will be randomly assigned to one of two groups: one group 17 will receive education with TE and the other group will receive education without TE. 18 Assessments will be made at baseline, mid-treatment, post-intervention, and at one and eight 19 months. **Outcomes:** The expected results of this study will shed light on the role of TE in pain 20 management and provide insight into its effects on BDNF levels. The intervention will also 21 provide an opportunity to biochemically measure the plastic changes, thereby improving our 22 understanding of its effects on brain plasticity. Conclusion: This study aims to determine the 23 applicability of therapeutic education as an effective non-pharmacological intervention for the 24 management of chronic pain. The rigorous scientific methods used ensure that the proposed 25 interventions will be clinically applicable across different health care systems.

26

Key Words: pain neuroscience education, brain derived neurotrophic factor, persistent pain,
physical therapy.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Strengths and limitations of this study

- The study will use a specifically pain oriented methodological approach that intends to
 go beyond purely informational pain neuroscience education, aiming for a more useful
 understanding of pain from patients.
- Incorporating the salutogenic model in therapeutic education will bring a health focused perspective to the research, potentially enriching its interpretive framework
 helping future interventions.
- The proposed use of clear and replicable guidelines such as GREET or TIDieR may
 help in the practical implementation challenge for clinicians, potentially influencing
 also the study's reproducibility.
- While the study plans to assess psychosocial factors, pain intensity levels, and brain
 plastic changes due to therapeutic education, this comprehensive approach might pose
 notable methodological challenges.
- Given the emerging field of brain plasticity related to therapeutic education in chronic
 pain patients, the limited existing research may influence the interpretive depth of the
 study's findings.
- 45

46 **Protocol version**

In this first version of the protocol dated July 2023, we are recruiting the sample, which is
planned to be completed in approximately two months (September 2023) in order to start the
trial in October 2023.

50

51 Funding

52 The study will be supported by funding received from CSEU La Salle N. 2022A36005.

53

54 Roles and responsibilities

Contributorship: Di Bonaventura Silvia^{1,2,3}, Fernández Carnero Josué^{2,3,4,5,6,7*}, Ferrer Peña
 Raúl^{3,5,6,8}

- ¹Escuela Internacional de Doctorado, Department of Physical Therapy, Occupational Therapy,
- 59 Rehabilitation and Physical Medicine, Rey Juan Carlos University, 28933 Alcorcón, Spain.

- 60 ².Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical
- 61 Medicine, Rey Juan Carlos University, 28922 Alcorcón, Spain.
- 62 ^{3.}Cognitive Neuroscience, Pain and Rehabilitation Research Group (NECODOR), Faculty of
- 63 Health Sciences, Rey Juan Carlos University, Madrid, Spain.
- ⁴.Grupo Multidisciplinar de Investigación y Tratamiento del Dolor, Grupo de Excelencia
- 65 Investigadora URJC-Banco de Santander, 28922 Madrid, Spain.
- ⁵ La Paz Hospital Institute for Health Research, IdiPAZ, 28029 Madrid, Spain.
- 67 ⁶Motion in Brains Research Group. Centro Superior de Estudios Universitarios La Salle,
- 68 Universidad Autonóma de Madrid, 28023 Madrid, Spain.
- ⁶⁹ ⁷ Grupo de Investigación de Dolor Musculoesqueletico y Control Motor, Universidad Europea
- 70 de Madrid, 28670 Villaviciosa de Odón, Spain.
- ⁸.Departamento de Fisioterapia, Facultad de Ciencias de la Salud, CSEU La Salle, Universidad
- 72 Autonóma de Madrid, 28023 Madrid, Spain.
- 73 *Corresponding author
- 74
- 75 Sponsor contact information: Raúl Ferrer Peña raul.ferrer@lasallecampus.es
- 76 Sponsor and funder: CSEU La Salle (UAM), Madrid.
- 77 Committees: Rey Juan Carlos University Ethical Committee.
- 78

79 Background

80 Chronic pain is a prevalent health problem that affects one in five people worldwide [1]. It is a debilitating condition that can have a significant impact on a person's quality of life. 81 82 affecting their ability to perform daily activities and decreasing their emotional and physical 83 well-being [2], as well as the resources needed to cope [3]. It is crucial to keep in mind one 84 serious drawback that accompanies chronic pain, the frequent dependence on drugs for pain 85 relief. In particular, the use of opioids has become one of the main medications for treating 86 pain, but at the same time, one of the causes of the increase in mortality due to overdose [4]. However, physiotherapy modalities that include therapeutic education and exercise are a 87 88 common non-pharmacological therapeutic approach for chronic pain and its maladaptive 89 plasticity [6]–[8], defined as a change in the structure or function of the nervous system that 90 results in increased pain sensitization [9], [10]. Specifically, therapeutic education (TE) plays 91 a particularly important role in reversing maladaptive plasticity, reducing pain, disability, fear-92 avoidance, and pain catastrophizing, among other aspects [11] TE is a fundamental component 93 in the management of chronic pain and addresses a variety of topics that are essential for

94 improving patients' quality of life [12], [13]. These topics include understanding pain and its 95 mechanism of production [14], promoting self-regulation and self-care strategies [15], 96 acquiring coping skills [16], reducing fear-avoidance and pain catastrophizing [17], as well as 97 promoting healthy lifestyles and optimizing physical functionality[18]. One of the main goals 98 for the patient is to reconfigure maladaptive beliefs associated with their chronic pain, 99 involving a change in the structure and function of the nervous system that has contributed to 100 increased pain sensitization [19], [20].

101 However, not any type of educational approach is sufficient to achieve this. There are 102 many types of therapeutic education, addressing different topics [21], [22] and using different 103 dosages [23]–[25], which inevitably lead to different results [26]–[28]. A specific approach is 104 required that considers both the biological and behavioral aspects of chronic pain. Furthermore, 105 in order to accurately determine the true impact of this type of non-only-informative 106 intervention, it is imperative to measure and evaluate the effects of the TE not only in terms of 107 perceived pain and psychosocial factors, but also through the lens of brain plasticity biomarkers 108 and draw correlations within these domains.

109 In this sense, it is essential to consider biological components such as brain-derived 110 neurotrophic factor (BDNF) and its relationship to cerebral plasticity in patients with persistent 111 pain [29], [30]. BDNF, a protein that plays an important role in pain sensitization and neuronal 112 plasticity, has been associated with neuronal hyperexcitability in chronic pain [31]. 113 Understanding its relationship to pain is crucial for developing new therapies. Manipulating 114 BDNF expression could offer options for modulating neuronal plasticity and relieving pain in 115 patients with chronic pain. However, the impact of these interventions on the adaptive changes in the brain, which are crucial in patients with persistent pain, remains largely unknown. 116 117 Additionally, the lack of adherence to established guidelines for reporting interventions, such 118 as the TIDieR checklist for general interventions [32], or GREET checklist for educational 119 interventions [33] and the CERT checklist for exercise interventions [34]hinders their 120 replication and adaptation to individual patients, thus limiting their practical utility [35].

In summary, despite the challenges that exist in the field of education and exercise for chronic pain management, this model of pain therapeutic education will address the mentioned needs, providing a comprehensive and evidence-based approach that considers changes in brain plasticity learning related, biobehavioral aspects, appropriate dosing, and objective evaluation of results.

126

127 Materials and Methods

128

129 Study Setting

This proposed study is a single-blind, parallel-group, randomized control trial. This study 130 131 protocol follows the structure based on the PICO question (Population, Intervention, 132 Comparison, Outcome) [36] and adheres to the recommendations of the Standard Protocol 133 Items: Recommendations for Interventional Trials (SPIRIT) guideline [37]. In addition, specific interventions were described based on the Template for Intervention Description and 134 135 Replication (TIDieR) checklist [32], the Guideline for Reporting Evidence-based practice 136 Educational interventions and Teaching (GREET) [33], and the Consensus on Exercise 137 Reporting Template (CERT) checklist [34]. The trial has been approved by the ethics 138 committee of Rey Juan Carlos University (Ethical number: 1901202202822) and the entire 139 study will be conducted at the Universidad Rey Juan Carlos located in Alcorcón, Madrid 140 (Spain). The trial identifier code is NCT05623579, and it was registered on November 18, 141 2022, in ClinicalTrials.gov.

142

143 Eligibility criteria

144 Patients will be recruited from the physical therapy clinics located in Madrid. Spain. The 145 participants will be included according to the following inclusion criteria: aged between 18 and 146 65, having a history of pain lasting more than twelve weeks, pain of at least 3 out of 10 on the visual analogue scale, possessing the ability to comprehend, speak, and write in Spanish, not 147 148 currently undergoing any other treatments up to 3 months prior to the study, and explicitly 149 accepting that they will not be allowed to initiate new treatments until the end of the follow-up 150 period. The exclusion criteria are neurological cognitive alteration that prevents understanding 151 the contents of the educational program (in case of doubt, assessment with the Mini Mental test 152 will be conducted with minimum score of 25 required), systemic, oncological or inflammatory 153 diseases; psychiatric pathologies, pregnancy, diabetes type II and the lack of ability to adhere 154 to protocol.

155

The following professionals were selected to carry out the study: two physiotherapists with more than 15 years of experience in the treatment of chronic pain for the pain education and exercise therapy component, two nurses for blood collection, another physiotherapist for

administering questionnaires on psychosocial variables and quantitative sensory testing, andtwo biochemists for the analysis of BDNF.

161

162 Interventions

All patients who meet the inclusion criteria and agree to participate in the study will be informed verbally and in writing with the delivery of the information sheet of the specific characteristics of the study. They will be asked to sign the written informed consent form to agree to participate.

- Sociodemographic data will then be collected and psychosocial variables on their current pain process. This data collection will be carried out in a room located in the physiotherapy gymnasium of the university center, previously designated for measurements by the evaluating researcher as well as blood extraction.
- Once the specific questionnaires and the pressure pain threshold (PPT) at the joints of the elbow 171 172 and tibialis anterior are measured, a trained professional will collect 5 ml of blood from the ulnar vein of the participants in a citrate vacutainer. The collection of the blood sample will 173 174 always take place between 6 and 7 p.m. to minimize the possible effects of circadian changes 175 [38]–[40]. Blood samples will be collected in tubes containing K3-EDTA and centrifuged at 1000 g for 10 min at 4 °C. The supernatants for the total plasma (TP) condition shall be frozen 176 177 at -80°C. Blood collection will be performed in both groups at rest before the intervention, 15 178 days after the intervention, at the end of the intervention period, 1 month and 8 months after 179 the intervention.
- After the initial data collection, a researcher other than the initial evaluator, and the physiotherapist-therapist who will apply the subsequent treatment to ensure blinding, will proceed to randomly assign the subjects to one of the two study branches by means of a list previously generated with GraphPad software (version 5.01 Graphpad software, Inc. San Diego, California, USA).
- 185

186 Intervention group (Exercise + POBTE)

Patients assigned to the intervention group will be instructed by a physiotherapist in the performance of the therapeutic exercise sessions according to their functional capacity, taking as a reference their HRmax [41]. They will be prescribed the reference intensity measures for the expected increase in training time and indications on potential risks, and references for the interruption of the exercise in their case. The total duration of the exercise program will be 4

192 weeks, with 3 sessions of a maximum of 45 minutes per session. On alternate days, twice a

- 193 week the patient will receive Pain Oriented Biobehavioral Therapeutic Education (POBTE)
- 194 sessions, focusing on the specific parameters described below and. The duration of the sessions
- 195 will be a maximum of 45 minutes each day [42], and the education program will be 8 sessions,
- 196 over 4 weeks. The intervention group will be instructed to refrain from discussing treatment
- 197 details with participants assigned to the control group until the end of the treatment and follow-
- 198 up period.
- 199 The main learning areas that will be addressed and the biobehavioral interventions proposed
- are summarized in Figure S2, and all the conceptual framework of the POBTE intervention is
- 201 explained in more detail in Annex S4. The specific cognitive components of the intervention
- are listed in the general intervention checklist, following the TiDier checklist (see Annex S1),
- also the exercise intervention is presented in Annex S2 with the CERT checklist, and the
- 204 Therapeutic Educational Intervention is presented in Annex S3 with the GREET checklist.



205

206 Fig. S2. POBTE's strategies.

- 208 A chronological representation of the tasks to be performed during the POBTE intervention is
- 209 presented in Figure S3. This figure is arranged to correspond to the stages of the meaningful
- 210 learning phase within the intervention design.

Pain Oriented Biobehavioral	Week 1		Week 2		Week 3		Week 4		
Therapeutic Education									
•	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	
MEANINGFUL LEARNING CORRESPONDANCE	S. S.	ţĊ}	Q	-`\$.	\bigcirc		đ	Ţ	
Presentation, motivational interview and therapeutic contract									
Reconceptualization of pain (1st part): damage and pain, subjectivity									
Motor imagery (Observed Actions + Explicit Imagery)									
First part concepts comprehension test and recall									
Reconceptualization of pain (2nd part): neuroplasticity and homunculus									
Beliefs + expectations (influence on pain perception, coping behavior)									
Self-management of sensory aspects (coping strategies, recovery times)									
Recall new concepts (1st and 2nd part)									
General treatment feedback according to the profile*									
Reconceptualization of pain (3rd part): context, attention, memory									
Recall new concepts first to third part + test									
Motor imagery dosage test and strengthen concept									
Recall of beliefs and expectations part									
Stress management skills and sleep disturbances on pain									
Reconceptualization of pain (4th part): relapses, social support									
Setting future goals and objectives									
Self-monitoring (Review of pain diaries)									
Global assessment of education (ad hoc concepts exam)									
Individualised take Home Messages and Feedback on the evolution									
*Explanation: depression, kinesiophobia, anxiety, catastrophism (rumination, magnifying) profil	e.		Cognitive A	rea 🧰	Skills	Area 🗧	Affe	ctive Area	

Meaningful Learning Based Design:



212

213 Fig. S3. POBTE's intervention.

214

215 Active Control group (Exercise)

Patients assigned to the active control group will be instructed by a physiotherapist in the performance of therapeutic exercise sessions according to their functional capacity, taking as a reference their HRmax. They will be prescribed the reference intensity measures for the expected increase in training time and indications on potential risks, and references for the interruption of the exercise in their case. The total duration of the exercise program will be 4 weeks, with 3 sessions of a maximum of 45 minutes per session. Contents of the exercise intervention are described in the CERT checklist (Annex S2).

224 Interventions modifications

Criteria for discontinuing or modifying allocated interventions for a given trial participant may include participant request, adverse events or harms, improved or worsened disease, and noncompliance. In the context of this study, criteria will be adapted to the specific needs and characteristics of the study population.

229

230 Interventions adherence

To improve adherence, we will provide clear instructions, personalized feedback and support, simplify the intervention as much as possible without losing scientific rigor, and monitor attendance, self-reports, and reminders. Written materials and videos will be provided, along with personalized feedback, progress reports, and regular check-ins. The attendance, selfreports and reminders will be used to monitor adherence.

236

237 **Outcomes**

238 **Primary outcome**

239 Pain intensity

Visual Analogue Scale (VAS): Pain intensity will be measured using a 100 mm visual analogue scale where 0 represented 'no pain' and 100 the 'worst pain imaginable'. Participants draw a mark at a point on the line that best reflects the pain they are experiencing at the time of measurement. Higher scores indicate higher pain levels. The sensitivity and specificity of this questionnaire and the acceptability of its psychometric properties have been previously approved [43].

246

247 Secondary outcomes

248 Biochemical

249 Plasma BDNF levels: Within 30 minutes after collection, blood samples shall be 250 centrifuged and the plasma separated into 0.5 ml aliquots for further analysis. Plasma BDNF 251 levels shall be determined by enzyme-linked immunosorbent assay (ELISA) test using 252 monoclonal antibodies specific for neurotrophin (R&D Systems, Minneapolis, MN) using the 253 manufacturer's protocol. All samples shall be tested in duplicate to avoid intra-assay variations. 254 The lower limit of detection for BDNF from the kit is 7.8 pg/mL. Assay (ELISA) using a 255 ChemiKine BDNF ELISA kit, CYT306 (Chemicon/Millipore, Billerica, MA). Optical density 256 will be measured using an ELISA reader at a wavelength of 450 nm (GloMax-Multi Microplate

Reader, Promega, Madison, WI) for multiplex assay measurements. Data will be expressed in
 pg/mg protein.

259

260 Psychosocial

Anxiety and depression: will be assessed using the Spanish validated version of the HADS self-completion scale. This scale is divided into two subscales of 7 items each: 1) depression (HADSDep); and 2) anxiety (HADSAnx). The HADS has demonstrated good reliability and validity in various pathologies [45].

Quality of life: measured with the EuroQoL-5D questionnaire (EQ-5D), it is a selfreport instrument to assess health-related quality of life composed of three items, a 5-factor descriptive scale, a second item composed of a vertical VAS and a social values index generated by the instrument. The EQ-5D has shown good psychometric characteristics [46].

Catastrophism: will be measured with the Spanish version of the Pain Catastrophism
 Scale (ECD). This has demonstrated adequate psychometric characteristics for the assessment
 of this construct with internal validity (Cronbach's alpha 0.81) [47].

272 *Chronic Pain Grading Scale (CPGS):* is a self-report instrument consisting of an 8-item 273 scale. It has a high internal consistency, Cronbach's α is 0.87, similar to that of other language 274 versions, and the intraclass correlation coefficient is 0.81. The average administration time is 275 2 min 28 s [48].

Tampa Scale for Kinesiophobia (TSK): is a self-report questionnaire that consists of 17
items. The internal consistency of the TSK has been reported to be high, with Cronbach's alpha
coefficients ranging from 0.74 to 0.93, indicating strong reliability. Test-retest reliability has
also been reported to be good, with correlation coefficients ranging from 0.75 to 0.88 [49].

Pittsburgh Sleep Quality Index (PSQI): is a self-rated questionnaire that consists of 19 items that are categorized into seven components, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The internal consistency of the PSQI has been reported to be high, with Cronbach's alpha coefficients ranging from 0.77 to 0.83, indicating strong reliability. Testretest reliability has also been reported to be good, with correlation coefficients ranging from 0.85 to 0.87 [50].

Perceived Stress Scale: is a self-report questionnaire that consists of 10 items, each
rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The internal consistency
of the PSS has been reported to be high, with Cronbach's alpha coefficients ranging from 0.78

to 0.91, indicating strong reliability. Test-retest reliability has also been reported to be good,
with correlation coefficients ranging from 0.67 to 0.85 [51].

- *International Physical Activity Questionnaire (IPAQ):* is a self-reported questionnaire that consists of 27 items that assess the frequency, duration, and intensity of physical activity. The internal consistency of the IPAQ has been reported to be moderate to high, with Cronbach's alpha coefficients ranging from 0.73 to 0.95. Test-retest reliability has also been reported to be good, with correlation coefficients ranging from 0.70 to 0.88 [52].
- 297 *Chronic Pain Self-Efficacy Scale (CPSS):* is a self-reported questionnaire that consists 298 of 22 items that are rated on a 0-10 scale, with higher scores indicating greater self-efficacy in 299 managing pain. The internal consistency of the CPSS has been reported to be high, with 300 Cronbach's alpha coefficients ranging from 0.89 to 0.95, indicating strong reliability. Test-301 retest reliability has also been reported to be good, with correlation coefficients ranging from 302 0.63 to 0.90 [53].
- 303 *Knowledge questionnaire on specific aspects of pain:* ad hoc, which includes 5 304 questions in multi-choice test format on the contents used in the education sessions.
- 305 *Global Perception of Change:* the only one that will be tested after the intervention. 306 This instrument consists of a 100mm line numbered in centimeters from -5 to 5 where the left 307 end reads "Much Worse", 0 is printed as "no change" and 5 is marked as "fully recovered". On 308 these values the patient is asked to answer the following question: "In relation to your pain, 309 how would you describe your current state of health compared to when your pain began?" This 310 version of the change perception scale has been assessed in the literature as the most 311 appropriate in musculoskeletal pain processes, and as a valid and reliable instrument [54].
- 312
- 313 Others
- 314

Pressure Pain Thresholds (PPT):

315 Pressure pain thresholds will be assessed using a pressure algometer. The algometer 316 will be applied to different points in the body (elbow and knee) and participants will be asked 317 to indicate the point at which pressure changes to pain. The pressure will be gradually increased 318 at a rate of approximately 1 kg/s until the participant indicates that they feel pain. The threshold 319 pressure at which the sensation changes from pressure to pain will be recorded in kilograms 320 (kg) and will be used as an indicator of pressure pain threshold. Higher PPT values indicate 321 higher pain thresholds. The validity and reliability of using a pressure algometer to measure 322 PPT have been previously established [44].

Height and Weight: both variables will be determined by patient estimation, with no exploration of these variables in the measurement process.

- 326 Sociodemographic
- 327 Age, Marital status (Single, Married, Divorced, Widowed), Employment status (Active,
- 328 Unemployed, Retired, Temporary disability, Student, Homemaker, Other), Educational level
- 329 (none, primary, secondary, university), Gender.
- 330 Exercise
- 331 Among the exercise variables, the parameters described below will be considered:
- 332 *Blood pressure and respiratory rate:* Measured with the Anura application, which has
- demonstrated a reliability with conventional blood pressure measurement of 98% [55].
- 334 *Saturation and HR:* Measured with an Oxylink finger pulse oximeter.
- All the outcome measurements will be assessed in a random order at baseline, at the halfway
- point of the treatment, post intervention, and one- and eight-months post intervention. (Figure
- 337 S4, S5 and S1).
- 338
- 339
- 340





342 Fig S4. Flow diagram

344 **Participants timeline**

- 345 We have included a schematic diagram outlining the time schedule of participant enrolment,
- interventions, assessments, and visits, as shown in the following figures (S4 and S5).





347

348 **Fig S5.** *Trial Timeline*

	STUDY PERIOD							
	Enrolment	Allocation		Post-allocation	1	Close-out		
Timepoint	t-1	0	t-baseline	t1 (15 days) t-postint		t3 (1 month later)	t4 (8 months later)	
ENROLMENT:								
Elegibility screen	x							
Informed consent	x							
Allocation		x						
INTERVENTIONS								
[POBTE + Exercise]			+					
[Exercise]			•					
ASSESMENTS								
Visual Analogue Scale			Х	х	Х	х	Х	
Pressure Pain Thresholds			х	х	х	х	Х	
Brain Derived Neurotrophic Factor			х	х	х	х	Х	
Hospital Anxiety and Depression Scale			х	х	х	х	Х	
Pain catastrophizing scale			х	х	х	х	Х	
Quality of Life			х	х	х	х	Х	
Chronic Pain Grading Scale			Х	х	Х	х	Х	
Tampa Scale for Kinesiophobia			х	х	х	х	Х	
Pittsburgh Sleep Quality Index			х	х	х	х	Х	
Perceived Stress Scale			х	х	х	х	Х	
International Physical Activity Questionnaire			Х	х	Х	х	Х	
Knowledge questionnaire			х	х	х	х	Х	
Global Perception of Change			х	х	Х	х	Х	
Height and Weight			х	х	х	х	Х	
Sociodemographic outcomes			х	х	Х	х	Х	
Blood pressure			х	х	х	х	Х	
Respiratory rate			х	х	Х	х	Х	
Saturation			Х	х	Х	х	Х	
HR			х	х	Х	х	Х	
GROC Scale							х	

349

Fig S1. *SPIRIT figure showing the schedule of enrolment, interventions, and assessments.*

351

352

353 Sample Size

354 The sample size was calculated using a t-test design for independent means, using the G*Power

program (Universität Düsseldorf, Germany) and establishing a significance level of 0.05 and a

356 power of 90%.

357 To determine the effect size, Cohen's d formula was used, which compares the mean difference

- 358 on the Visual Analogue Scale (VAS), set at 2 points, and the pooled standard deviation
- 359 (SDpooled). Based on data from a previous pilot study, the standard deviations for the
- intervention and control groups were 1.29 and 2.61 respectively. Using these data, the
- 361 SDpooled was calculated using the formula for independent groups: $sqrt[(((n1-1)*SD1^2 +$

 $(n2-1)SD2^2 / (n1+n2-2)$, yielding a value of 2.13 [56].

- 363 Therefore, the effect size (d) was calculated as 2/2.13 = 0.94. With an allocation ratio of 1:1
- between groups, these data were entered into GPower [57], resulting in the need for at least 25
 subjects per group to be able to detect a 2-point difference in VAS with 90% power.
- 366 Considering a loss rate of 25%, the final sample size was adjusted to 32 subjects per group.
- 367 Consequently, the study will require a total of 64 subjects to reach the required statistical
- 368 power.

369

370 Recruitment

371 To achieve our target sample size, from July to September 2023, we will partner with

- 372 physiotherapy clinics, distribute pamphlets, utilize social media, recruit through support groups
- and emphasize the benefits of the intervention.
- 374

375 Allocation

376 Sequence generation, concealment mechanism and implementation

Individuals who met the inclusion criteria will randomly be allocated to one of two treatment arms: (1) POBTE plus exercise or (2) exercise therapy, using computer-generated random numbers in stratified permuted block (block size of 4 and 6). The allocation will be concealed in an opaque, sealed envelope. A research assistant opens them and assigns patients to either of the treatment arms. The randomization will be conducted after signing the informed consent and baseline assessments.

383

384 Blinding

385 Masking

In this trial, outcome assessors and data analysts will be blinded after intervention assignment. They won't know the participants' intervention group during outcome assessment or data analysis. Due to the intervention's nature, involving educational sessions and exercises requiring interaction, participants and educators cannot be blinded.

390

391 Emergency unmasking

A secure process, such as a password-protected system, will be employed. Unblinding shouldonly occur when necessary, preserving the trial's integrity.

394

395 Data Collection plan

The trial will collect baseline and outcome data through questionnaires, laboratory tests, and physical assessments, with standardized and validated instruments to ensure data quality. The instruments used in the trial are validated, and information on them can be found in the protocol.

401 **Data collection plan: retention**

402 To ensure that participants remain engaged and complete the follow-up in our trial, we have 403 implemented several strategies. Firstly, we provide clear and concise information to our 404 participants regarding the trial, including potential benefits and risks, to help them understand 405 the importance of their participation. Secondly, we establish clear communication channels 406 between the research team and participants to encourage an open and trusting relationship, 407 where participants feel comfortable asking questions and providing feedback. Additionally, we 408 make sure to conduct regular follow-up phone calls or emails to remind participants of 409 upcoming study visits and address any concerns they may have.

410

411 Data Management

All data will be entered into a secure database system with restricted access, and data quality
will be maintained with range checks and double data entry. Data security and storage plans
include regular backups, restricted access, and secure transfer methods.

415

416 Statistics: outcome

417 Data analysis will be performed with SPSS statistical software version 25.0 (SPSS Inc.,

418 Chicago, IL, USA). A descriptive analysis of the demographic characteristics and pain intensity

419 of the sample will be performed, presenting continuous variables as Mean ± Standard Deviation

420 (SD), 95% Confidence Interval (CI), while categorical variables will be presented as Number

421 (n) and Percentage (relative frequency, %). If the quantitative variables follow a non-normal

422 distribution, they will be described with the median and the interquartile range.

Parametric tests (normal distribution) will be chosen for the comparison between groups based on the central limit theorem, since the sample size of both groups will be greater than 30. Therefore, the one-way ANOVA test will be used to analyze the group factor in the quantitative variables and the chi-square test for the qualitative variables. If the ANOVA reveals statistical significance, a post-hoc analysis with Bonferroni correction will be performed. A P-value < 0.05 will be accepted as statistically significant.

429

430 Statistics: additional analyses

We will conduct secondary analyses to examine treatment effects within specific subgroups ofparticipants and adjust for potential confounding variables. Subgroup analyses will consider

433 age, gender, and duration of pain. Multiple linear regression models will be used for adjusted

- 434 analyses, and sensitivity analyses will be conducted to assess the robustness of our results.
- 435

436 Statistics: Analyses population and missing data

The analysis will be based on the intention-to-treat principle, including all randomized participants in the analysis, regardless of their compliance with the intervention protocol. Missing data will be handled using appropriate imputation methods, such as multiple imputations or last observation carried forward. Sensitivity analyses will be conducted to evaluate the impact of different imputation methods on the results. The analysis population will be clearly defined and any deviations from the intention-to-treat principle will be reported and justified.

444

445 **Data monitoring: Formal committee**

This small-scale, low-risk intervention trial does not require a Data Monitoring Committee (DMC). Instead, the study investigators will take on the responsibility of monitoring trial data. The primary investigator will regularly review study data to ensure adherence to the protocol and to maintain the safety and well-being of participants. Should significant safety concerns or other issues arise, the primary investigator will collaborate with the study team and, if necessary, consult with an independent expert to determine the best course of action. Any concerns or protocol deviations will be reported to relevant regulatory authorities promptly.

453

454 **Data monitoring: Interim analysis**

Although data and blood samples will be collected at 15 days during the intervention period, no interim analyses are planned for this trial, although it might be interesting to see if there are possible changes in BDNF levels, as a biomarker of brain plasticity, in relation to the learning curve [58] experienced by the patients. It is expected that the learning process they experience during the intervention will lead to significant changes in BDNF levels.

460

461 Harms

The research team will monitor participants for adverse events related to the intervention or trial conduct. Solicited events will be assessed during follow-up visits, while spontaneously reported events will be identified during unscheduled interactions.

Adverse events will be documented, and the principal investigator will review them, determining if they require reporting to the ethics committee and regulatory authorities. Unintended effects of the trial interventions or conduct will also be monitored and managed.

468 All events will be reported in the trial report, publication, and to the ethical committee. 469

470 **Research ethics approval**

To get approval for our study from a research ethics committee (REC), we developed a detailed protocol, submitted necessary documentation, addressed any questions or concerns from the REC, obtained REC approval and will maintain ongoing compliance. We also have plans to communicate important protocol modifications to investigators, the REC, trial participants, trial registries, journals, and regulators.

476 **Consent or assent**

Informed consent or assent will be obtained from potential trial participants or authorized surrogates by trained research staff. The consent process will involve the use of written informed consent documents, which will be provided to the potential participants or their authorized surrogates in advance of the trial. The documents will include a description of the study, the risks and benefits of participation, and the rights and responsibilities of the participants. The research staff will also be available to answer any questions or concerns that may arise during the consent process.

484 **Consent or assent: ancillary studies**

We included in the informed consent form for potential ancillary studies involving participant data and biological specimens. The form will state that data and specimens may be used for future research with ethical approval, and participants could withdraw consent at any time. This ensured participants were fully informed and their rights and privacy were protected.

489

490 **Confidentiality**

We will protect participants' personal information throughout the trial. During screening, we will only collect necessary information, and destroy any unused data. Personal information will be kept secure and restricted to authorized members of the study team during the trial, identified only by participant ID numbers. After the trial, identifying information will be removed, and

data will be stored securely for a specified period. We will inform participants of ourconfidentiality policies during informed consent.

497 **Declaration of interests**

- 498 Despite receiving financial support for the project from a university to carry out the study, we
- 499 do not have any conflicts of interest to declare.
- 500

501 Data access

- 502 Access to the final trial dataset will be limited to authorized members of the research team, 503 including the principal investigators and their designated staff.
- 504

505 Ancillary and post-trial care

506 The study team will develop a plan for providing ancillary or post-trial care for harm to 507 participants during a clinical trial. They will inform participants about these plans during the 508 informed consent process and work with regulatory authorities and review boards to ensure 509 appropriate provisions are in place.

510

511 **Dissemination policy: Trial results**

We will communicate trial results to participants, healthcare professionals, and the public. Results will be published in a peer-reviewed journal, presented at conferences, and reported in publicly accessible databases. We'll provide lay summaries to participants and ensure healthcare professionals receive information. We'll publish regardless of the outcome, share the protocol, dataset and statistical analysis, and uphold responsible research guidelines. Our communication will be clear, timely, and accurate with integrity and transparency.

518

519 **Dissemination policy: Authorship**

Authorship eligibility guidelines will follow international standards [59]. Contributions of eligible individuals will be clearly stated in publications, while professional writers will only be acknowledged if they meet the authorship eligibility guidelines.

- 523
- 524
- 525

526 Dissemination policy: Reproducible research

527 After the study, we will share the full protocol, de-identified participant-level dataset, and 528 statistical analysis to encourage transparency and enable further research. We will provide 529 technical support and educational resources to promote accessibility and reproducibility of 530 study findings.

531

532 Discussion

The current randomized controlled trial (RCT) seeks to examine the impact of a specific 533 534 therapeutic education program, combined with exercise, on BDNF levels and pain perceived 535 intensity among individuals suffering from chronic musculoskeletal pain. This article not only 536 aims to offer a more rigorous approach to therapeutic education from a biobehavioral 537 perspective, but also assesses the outcomes of an intervention that encompasses both the cognitive aspect and pain-related plasticity biomarkers, such as BDNF. Consequently, it 538 539 represents a valuable contribution to low-cost, non-pharmacological treatments in 540 physiotherapy. Although the study design and methods have been meticulously planned, there 541 are several practical and operational considerations that need to be addressed.

542 One potential limitation of our study relates to the heterogeneity of chronic pain. 543 Despite having well-defined inclusion criteria, it is important to recognize that chronic pain is 544 a complex and multifactorial condition [60]–[62]. While we have not imposed restrictions on 545 the specific site of pain in our selection criteria, supported by evidence that chronic pain is 546 centrally mediated rather than solely dependent on the location of the injury [63]–[66], it is evident that various individual factors influence the pain experience in each patient [67]–[69], 547 548 which may impact the obtained results. To address this limitation, in addition to the inclusion 549 criteria, we will consider conducting subgroup analysis if necessary and feasible. This analysis 550 will allow us to examine possible clusters of patients with similar characteristics, which will 551 enhance our understanding of differences and treatment responses within our sample.

Another concern is the possible confounding effects of medications and other interventions that participants might be undergoing. To address this issue, participants will be strictly advised to continue their regular medication regimen (if applicable) but will not be permitted to initiate any new treatments during the program and follow-up period. This measure is implemented to minimize potential confounding factors and ensure the integrity of the study results. The study team will closely screen and monitor participants to ensure compliance with this requirement.

Additionally, statistical analysis will consider adjusting for any confounding variables that mayarise.

560 Finally, it is important to mention that the measurement of BDNF levels can pose challenges 561 due to the inherent variability in sample collection, storage, and analysis. In this study, BDNF 562 levels will be specifically measured in plasma samples, as they have been found to be more 563 stable during the analysis compared to serum samples [70]. To ensure precise and reliable 564 results, the study team will adhere to rigorous protocols for plasma sample collection, 565 processing, and storage. The analysis will be conducted using standardized ELISA kits with 566 regular calibration and quality control checks implemented to minimize potential sources of 567 variation. These measures are crucial for ensuring the accuracy and validity of the BDNF 568 measurements and upholding the integrity and reliability of the study's findings.

569 In conclusion, this randomized controlled trial (RCT) serves as a significant milestone in two 570 important aspects. Firstly, it contributes to the development of a more structured and rigorous 571 therapeutic education model for individuals with chronic musculoskeletal pain by 572 implementing validated checklists and protocols [32], [33]. This standardized approach ensures 573 the delivery of effective interventions tailored to the specific needs of these patients.

574 Secondly, the study investigates the changes occurring at the central nervous system level by 575 measuring biomarkers such as BDNF. This provides valuable insights into the underlying 576 mechanisms of chronic pain and the impact of non-pharmacological interventions on brain 577 plasticity. By elucidating the relationship between therapeutic education, BDNF levels, and 578 pain outcomes, this research can pave the way for novel and targeted strategies to enhance 579 treatment efficacy and improve the quality of life for individuals suffering from chronic pain.

581 Appendices

582

583 Informed consent materials

584 We will attach the model consent form and related documentation to the annexes section of our

study to ensure a clear record of the consent process that can be easily accessed and verified

586 by future reviewers.

587

588 **Biological specimens**

589 We will collect and label blood samples, isolate plasma, and measure BDNF levels using an

590 ELISA kit. Quality control measures will be in place to ensure accurate measurements.

591 Specimens will be stored in secure, monitored freezers (-80°) at the research site and laboratory,

and tracked using unique participant identifiers. With proper ethics approval and participant

593 consent, stored specimens may be used in future ancillary studies. This plan ensures the proper

handling and availability of biological specimens for future research.

595

596 Acknowledgments

597 This study is part of PhD thesis of Silvia Di Bonaventura and will be supported by Spanish

598 Ministry of Education (Grant number: FPU20/00041).

600

601 List of acronyms

Brain Derived Neurotrophic Factor
Consensus on Exercise Reporting Template
Chronic Pain
Chronic Pain Grading Scale
Chronic Pain Self-Efficacy Scale
Pain catastrophizing scale
EuroQol-5 Dimensions
Guideline for Reporting Evidence-based practice Educational interventions and
Teaching
Hospital Anxiety and Depression Scale
Heart Rate
International Physical Activity Questionnaire
Population, Intervention, Control, Outcomes
Pressure Pain Threshold
Pain Oriented Biobehavioral Therapeutic Education
Pittsburgh Sleep Quality Index
Perceived Stress Scale
Research Ethic Committee
Randomized Controlled Trial
Standard Protocol Items: Recommendations for Interventional Trial
Therapeutic Education
Template for Intervention Description and Replication
Total Plasma
Tampa Scale for Kinesiophobia
Visual Analogue Scale

603 References

604		
605	[1]	R. D. Treede et al., "Chronic pain as a symptom or a disease: The IASP Classification
606		of Chronic Pain for the International Classification of Diseases (ICD-11)," Pain, vol.
607		160, no. 1. Lippincott Williams and Wilkins, pp. 19–27, Jan. 01, 2019. doi:
608		10.1097/j.pain.00000000001384.
609	[2]	S. E. E. Mills, K. P. Nicolson, and B. H. Smith, "Chronic pain: a review of its
610		epidemiology and associated factors in population-based studies," Br J Anaesth, vol.
611		123, no. 2, pp. e273-e283, Aug. 2019, doi: 10.1016/j.bja.2019.03.023.
612	[3]	A. Büssing, T. Ostermann, E. Am Neugebauer, and P. Heusser, "Adaptive coping
613		strategies in patients with chronic pain conditions and their interpretation of disease,"
614		2010. [Online]. Available: http://www.biomedcentral.com/1471-2458/10/507
615	[4]	W. Häuser, T. Schubert, T. Vogelmann, C. Maier, M. A. Fitzcharles, and T. Tölle,
616		"All-cause mortality in patients with long-term opioid therapy compared with non-
617		opioid analgesics for chronic non-cancer pain: A database study," BMC Med, vol. 18,
618		no. 1, Jul. 2020, doi: 10.1186/s12916-020-01644-4.
619	[5]	W. Häuser, T. Schubert, T. Vogelmann, C. Maier, M. A. Fitzcharles, and T. Tölle,
620		"All-cause mortality in patients with long-term opioid therapy compared with non-
621		opioid analgesics for chronic non-cancer pain: A database study," BMC Med, vol. 18,
622		no. 1, Jul. 2020, doi: 10.1186/s12916-020-01644-4.
623	[6]	S. J. Snodgrass, N. R. Heneghan, H. Tsao, P. T. Stanwell, D. A. Rivett, and P. M. Van
624		Vliet, "Recognising neuroplasticity in musculoskeletal rehabilitation: A basis for
625		greater collaboration between musculoskeletal and neurological physiotherapists,"
626		Man Ther, vol. 19, no. 6, pp. 614-617, Dec. 2014, doi: 10.1016/j.math.2014.01.006.
627	[7]	E. Dayan and L. G. Cohen, "Neuroplasticity subserving motor skill learning," Neuron,
628		vol. 72, no. 3. pp. 443-454, Nov. 03, 2011. doi: 10.1016/j.neuron.2011.10.008.
629	[8]	J. El-Sayes, D. Harasym, C. V. Turco, M. B. Locke, and A. J. Nelson, "Exercise-
630		Induced Neuroplasticity: A Mechanistic Model and Prospects for Promoting
631		Plasticity," Neuroscientist, vol. 25, no. 1. SAGE Publications Inc., pp. 65-85, Feb. 01,
632		2019. doi: 10.1177/1073858418771538.
633	[9]	C. J. Woolf, "Central sensitization: Implications for the diagnosis and treatment of
634		pain," Pain, vol. 152, no. SUPPL.3. Mar. 2011. doi: 10.1016/j.pain.2010.09.030.

- [10] X. Y. Li, Y. Wan, S. J. Tang, Y. Guan, F. Wei, and D. Ma, "Maladaptive Plasticity and
 Neuropathic Pain," *Neural Plasticity*, vol. 2016. Hindawi Publishing Corporation,
 2016. doi: 10.1155/2016/4842159.
- 638 [11] A. Louw, J. Nijs, and E. J. Puentedura, "A clinical perspective on a pain neuroscience
 639 education approach to manual therapy," *Journal of Manual and Manipulative Therapy*,
 640 vol. 25, no. 3, pp. 160–168, May 2017, doi: 10.1080/10669817.2017.1323699.
- [12] I. Saracoglu, M. I. Arik, E. Afsar, and H. H. Gokpinar, "The short-term effects of
 neuroscience pain education on quality of life in patients with chronic low back pain:
 A single-blinded randomized controlled trial," *Eur J Integr Med*, vol. 33, Jan. 2020,
 doi: 10.1016/j.eujim.2019.101046.
- [13] I. Saracoglu, M. I. Arik, E. Afsar, and H. H. Gokpinar, "The effectiveness of pain neuroscience education combined with manual therapy and home exercise for chronic low back pain: A single-blind randomized controlled trial," *Physiother Theory Pract*, vol. 38, no. 7, pp. 868–878, 2022, doi: 10.1080/09593985.2020.1809046.
- M. Meeus, J. Nijs, J. Van Oosterwijck, V. Van Alsenoy, and S. Truijen, "Pain
 physiology education improves pain beliefs in patients with chronic fatigue syndrome
 compared with pacing and self-management education: A double-blind randomized
 controlled trial," *Arch Phys Med Rehabil*, vol. 91, no. 8, pp. 1153–1159, 2010, doi:
 10.1016/j.apmr.2010.04.020.
- [15] I. Aguirrezabal *et al.*, "Effectiveness of a primary care-based group educational
 intervention in the management of patients with migraine: A randomized controlled
 trial," *Prim Health Care Res Dev*, 2019, doi: 10.1017/S1463423619000720.
- 657 [16] A. Malfliet *et al.*, "Blended-learning pain neuroscience education for people with
 658 chronic spinal pain: Randomized controlled multicenter trial," *Phys Ther*, vol. 98, no.
 659 5, pp. 357–368, May 2018, doi: 10.1093/ptj/pzx092.
- 660 [17] J. A. Watson *et al.*, "Pain Neuroscience Education for Adults With Chronic
- 661Musculoskeletal Pain: A Mixed-Methods Systematic Review and Meta-Analysis,"662Journal of Pain, vol. 20, no. 10. Churchill Livingstone Inc., pp. 1140.e1-1140.e22,6620.1.01.010.lii.10.1010/lii.ii.0010.02.011
- 663 Oct. 01, 2019. doi: 10.1016/j.jpain.2019.02.011.
- A. Louw, I. Diener, D. S. Butler, and E. J. Puentedura, "The effect of neuroscience
 education on pain, disability, anxiety, and stress in chronic musculoskeletal pain," *Archives of Physical Medicine and Rehabilitation*, vol. 92, no. 12. pp. 2041–2056,
 Dec. 2011. doi: 10.1016/j.apmr.2011.07.198.

668 [19] A. May, "Chronic pain may change the structure of the brain," *Pain*, vol. 137, no. 1.

669 pp. 7–15, Jun. 30, 2008. doi: 10.1016/j.pain.2008.02.034.

- 670 [20] R. F. Smallwood et al., "Structural brain anomalies and chronic pain: A quantitative
- 671 meta-analysis of gray matter volume," *Journal of Pain*, vol. 14, no. 7. pp. 663–675,
 672 Jul. 2013. doi: 10.1016/j.jpain.2013.03.001.
- 673 [21] B. F. Dear *et al.*, "The pain course: A randomised controlled trial comparing a remote-674 delivered chronic pain management program when provided in online and workbook
- 675 formats," *Pain*, vol. 158, no. 7, pp. 1289–1301, Jul. 2017, doi:
- 676 10.1097/j.pain.000000000000916.
- 677 [22] M. Mehlsen, L. Hegaard, E. Ørnbøl, J. S. Jensen, P. Fink, and L. Frostholm, "The
- 678 effect of a lay-led, group-based self-management program for patients with chronic

pain: A randomized controlled trial of the Danish version of the Chronic Pain Self-

- 680 Management Programme," *Pain*, vol. 158, no. 8, pp. 1437–1445, Aug. 2017, doi:
- 681 10.1097/j.pain.000000000000931.
- 682 [23] "darnall2021".
- 683 [24] G. Lorimer Moseley, M. K. Nicholas, and P. W. Hodges, "A Randomized Controlled
 684 Trial of Intensive Neurophysiology Education in Chronic Low Back Pain."
- R. B. Saper *et al.*, "Yoga, physical therapy, or education for chronic low back pain: A
 randomized noninferiority trial," *Ann Intern Med*, vol. 167, no. 2, pp. 85–94, Jul. 2017,
 doi: 10.7326/M16-2579.
- 688 [26] A. Louw, E. J. Puentedura, K. Zimney, and S. Schmidt, "Know Pain, know gain? A
 689 perspective on pain neuroscience education in physical therapy," *Journal of*
- 690 Orthopaedic and Sports Physical Therapy, vol. 46, no. 3. Movement Science Media,

691 pp. 131–134, Mar. 01, 2016. doi: 10.2519/jospt.2016.0602.

- [27] L. J. Geneen *et al.*, "Effects of education to facilitate knowledge about chronic pain for
 adults: A systematic review with meta-analysis," *Syst Rev*, vol. 4, no. 1, Oct. 2015, doi:
 10.1186/s13643-015-0120-5.
- 695 [28] L. Wood and P. A. Hendrick, "A systematic review and meta-analysis of pain
 696 neuroscience education for chronic low back pain: Short-and long-term outcomes of
- 697 pain and disability," *European Journal of Pain (United Kingdom)*, vol. 23, no. 2.
- 698 Blackwell Publishing Ltd, pp. 234–249, Feb. 01, 2019. doi: 10.1002/ejp.1314.
- 699 [29] A. Merighi et al., "BDNF as a pain modulator," Progress in Neurobiology, vol. 85, no.
- 700 3. pp. 297–317, Jul. 2008. doi: 10.1016/j.pneurobio.2008.04.004.

701 [30] T. Brigadski and V. Leßmann, "BDNF: a regulator of learning and memory processes 702 with clinical potential," eNeuroforum, vol. 5, no. 1, pp. 1–11, Mar. 2014, doi: 703 10.1007/s13295-014-0053-9. 704 J. Nijs *et al.*, "Brain-derived neurotrophic factor as a driving force behind [31] 705 neuroplasticity in neuropathic and central sensitization pain: A new therapeutic 706 target?," Expert Opinion on Therapeutic Targets, vol. 19, no. 4. Informa Healthcare, 707 pp. 565–576, Apr. 01, 2015. doi: 10.1517/14728222.2014.994506. 708 T. C. Hoffmann et al., "Better reporting of interventions: Template for intervention [32] 709 description and replication (TIDieR) checklist and guide," BMJ (Online), vol. 348, 710 Mar. 2014, doi: 10.1136/bmj.g1687. A. C. Phillips et al., "Development and validation of the guideline for reporting 711 [33] 712 evidence-based practice educational interventions and teaching (GREET)," BMC Med 713 Educ, vol. 16, no. 1, Sep. 2016, doi: 10.1186/s12909-016-0759-1. 714 S. C. Slade et al., "Consensus on Exercise Reporting Template (CERT): Modified [34] Delphi Study," 2016. [Online]. Available: http://www.equator-715 716 E. K.-Y. H. P. H. F. C. G.-M. O. V.-A. and J. M.-S. Javier Martinez-Calderon, "A Call [35] 717 for Improving Research on Pain Neuroscience Education and Chronic Pain: An 718 Overview of Systematic Reviews," Journal of Orthopaedic & Sports Physical 719 *Therapy*, vol. 53:6, pp. 353–368, 2023. 720 [36] S. Aslam and P. Emmanuel, "Formulating a researchable question: A critical step for 721 facilitating good clinical research," Indian Journal of Sexually Transmitted Diseases, 722 vol. 31, no. 1. pp. 47–50, Jan. 01, 2010. doi: 10.4103/0253-7184.69003. A. W. Chan et al., "SPIRIT 2013 statement: Defining standard protocol items for 723 [37] 724 clinical trials," Annals of Internal Medicine, vol. 158, no. 3. American College of 725 Physicians, pp. 200-207, Feb. 05, 2013. doi: 10.7326/0003-4819-158-3-201302050-726 00583.

- [38] S. W. Cain *et al.*, "Circadian rhythms in plasma brain-derived neurotrophic factor
 differ in men and women," *J Biol Rhythms*, vol. 32, no. 1, pp. 75–82, Feb. 2017, doi:
 10.1177/0748730417693124.
- [39] S. W. Choi, S. Bhang, and J. H. Ahn, "Diurnal variation and gender differences of
 plasma brain-derived neurotrophic factor in healthy human subjects," *Psychiatry Res*,
 vol. 186, no. 2–3, pp. 427–430, Apr. 2011, doi: 10.1016/j.psychres.2010.07.028.
- [40] A. A. H. Ali and C. von Gall, "Adult Neurogenesis under Control of the Circadian
 System," *Cells*, vol. 11, no. 5. MDPI, Mar. 01, 2022. doi: 10.3390/cells11050764.

735 [41] C. J. Keating et al., "Utilizing Age-Predicted Heart Rate Maximum to Prescribe a Minimally Invasive Cycle Ergometer HIIT Protocol in Older Adults: A Feasibility 736 737 Study." [Online]. Available: http://www.intjexersci.com 738 J. J. Amer-Cuenca *et al.*, "How much is needed? Comparison of the effectiveness of [42] 739 different pain education dosages in patients with fibromyalgia," Pain Medicine (United 740 States), vol. 21, no. 4, pp. 782–793, 2020, doi: 10.1093/PM/PNZ069. A. M. Boonstra, H. R. Schiphorst Preuper, M. F. Reneman, J. B. Posthumus, R. E. 741 [43] 742 Stewart, and R. Friesland, "Reliability and validity of the visual analogue scale for 743 disability in patients with chronic musculoskeletal pain," Wolters Kluwer Health 744 Lippincott Williams & Wilkins, 2008. [44] A. M. Kinser, W. A. Sands, and M. H. Stone, "RELIABILITY AND VALIDITY OF 745 746 A PRESSURE ALGOMETER." [Online]. Available: www.nsca-jscr.org M. Carmen Terol-Cantero, V. Cabrera-Perona, and M. Martín-Aragón, "Revisión de 747 [45] 748 estudios de la Escala de Ansiedad y Depresión Hospitalaria (HAD) en muestras 749 españolas1 macarmen@umh.es," Anales de Psicologia, vol. 31, no. 2, pp. 494–503, 750 2015, doi: 10.6018/analesps.31.2.172701. 751 J. M. Cabasés, "The EQ-5D as a measure of health outcomes," Gac Sanit, vol. 29, no. [46] 752 6, pp. 401–403, Nov. 2015, doi: 10.1016/j.gaceta.2015.08.007. 753 [47] "CATASTR". 754 [48] R. Ferrer-Peña, A. Gil-Martínez, J. Pardo-Montero, V. Jiménez-Penick, T. Gallego-755 Izquierdo, and R. La Touche, "Adaptación y validación de la Escala de gradación del 756 dolor crónico al español," Reumatol Clin, vol. 12, no. 3, pp. 130-138, May 2016, doi: 757 10.1016/j.reuma.2015.07.004. S. R. Woby, N. K. Roach, M. Urmston, and P. J. Watson, "Psychometric properties of 758 [49] 759 the TSK-11: A shortened version of the Tampa Scale for Kinesiophobia," Pain, vol. 760 117, no. 1–2, pp. 137–144, Sep. 2005, doi: 10.1016/j.pain.2005.05.029. 761 [50] C. L. Larche, I. Plante, M. Roy, P. M. Ingelmo, and C. E. Ferland, "The Pittsburgh 762 Sleep Quality Index: Reliability, Factor Structure, and Related Clinical Factors among Children, Adolescents, and Young Adults with Chronic Pain," Sleep Disord, vol. 2021, 763 764 pp. 1-8, Apr. 2021, doi: 10.1155/2021/5546484. E. H. Lee, "Review of the psychometric evidence of the perceived stress scale," Asian 765 [51] 766 Nursing Research, vol. 6, no. 4. pp. 121–127, Dec. 2012. doi: 767 10.1016/j.anr.2012.08.004.

- 768 [52] C. L. Craig *et al.*, "International physical activity questionnaire: 12-Country reliability
- 769 and validity," *Med Sci Sports Exerc*, vol. 35, no. 8, pp. 1381–1395, Aug. 2003, doi:
- 770 10.1249/01.MSS.0000078924.61453.FB.
- [53] S. T. Cheng *et al.*, "Developing a short multidimensional measure of pain selfefficacy: The chronic pain self-efficacy scale-short form," *Gerontologist*, vol. 60, no.
- 773 3, pp. E127–E136, Apr. 2020, doi: 10.1093/geront/gnz041.
- 774 [54] "gLOBAL RAtINg OF ChANge sCALes: A RevIew OF stReNgths AND
 775 weAkNesses AND CONsIDeRAtIONs FOR DesIgN."
- C. Pham *et al.*, "Effectiveness of consumer-grade contactless vital signs monitors: a
 systematic review and meta-analysis," *Journal of Clinical Monitoring and Computing*,
 vol. 36, no. 1. Springer Science and Business Media B.V., pp. 41–54, Feb. 01, 2022.
 doi: 10.1007/s10877-021-00734-9.
- 779 doi: 10.1007/s10877-021-00734-9.
- [56] J., H. N. Cohen, "Statistical power analysis for the behavioral sciences (2nd ed.)...,"
 Lawrence Erlbaum Associates, 1988.
- F., E. E., L. A.-G., & B. A. Faul, "G*Power 3: A flexible statistical power analysis
 program for the social, behavioral, and biomedical sciences.," *Behavior Research Methods*, *39*, *175–191*..
- [58] J. M. J. Murre and J. Dros, "Replication and analysis of Ebbinghaus' forgetting curve,"
 PLoS One, vol. 10, no. 7, Jul. 2015, doi: 10.1371/journal.pone.0120644.
- [59] I. Vartiovaara, "Guidelines on authorship. International committee of medical journal
 editors," *Br Med J (Clin Res Ed)*, vol. 291, no. 6497, p. 722, 1985, doi:
- 789 10.1136/bmj.291.6497.722.
- [60] I. Kela *et al.*, "Chronic Pain: A Complex Condition With a Multi-Tangential
 Approach," *Cureus*, Nov. 2021, doi: 10.7759/cureus.19850.
- 792 [61] B. Sherriff, C. Clark, C. Killingback, and D. Newell, "Impact of contextual factors on
- patient outcomes following conservative low back pain treatment: systematic review,"
- 794 *Chiropractic and Manual Therapies*, vol. 30, no. 1. BioMed Central Ltd, Dec. 01,
- 795 2022. doi: 10.1186/s12998-022-00430-8.
- G. Rossettini, E. Carlino, and M. Testa, "Clinical relevance of contextual factors as
 triggers of placebo and nocebo effects in musculoskeletal pain," *BMC Musculoskeletal Disorders*, vol. 19, no. 1. BioMed Central Ltd., Jan. 22, 2018. doi: 10.1186/s12891018-1943-8.
- 800 [63] M. M. Volcheck, S. M. Graham, K. C. Fleming, A. B. Mohabbat, and C. A. Luedtke,
 801 "Central sensitization, chronic pain, and other symptoms: Better understanding, better

802		management," Cleveland Clinic journal of medicine, vol. 90, no. 4. NLM (Medline),
803		pp. 245–254, Apr. 03, 2023. doi: 10.3949/ccjm.90a.22019.
804	[64]	MA. Fitzcharles, S. P. Cohen, D. J. Clauw, G. Littlejohn, C. Usui, and W. Häuser,
805		"Chronic Pain 2 Nociplastic pain: towards an understanding of prevalent pain
806		conditions," 2021. [Online]. Available: www.thelancet.com
807	[65]	A. Latremoliere and C. J. Woolf, "Central Sensitization: A Generator of Pain
808		Hypersensitivity by Central Neural Plasticity," Journal of Pain, vol. 10, no. 9. pp.
809		895–926, Sep. 2009. doi: 10.1016/j.jpain.2009.06.012.
810	[66]	J. Nijs et al., "Central sensitisation in chronic pain conditions: latest discoveries and
811		their potential for precision medicine," The Lancet Rheumatology, vol. 3, no. 5. Lancet
812		Publishing Group, pp. e383-e392, May 01, 2021. doi: 10.1016/S2665-9913(21)00032-
813		1.
814	[67]	S. J. Linton, W. S. Shaw, and W. S. Shaw, "Impact of Psychological Factors in the
815		Experience of Pain," 2011. [Online]. Available:
816		https://academic.oup.com/ptj/article/91/5/700/2735743
817	[68]	L. M. Tracy, "Psychosocial factors and their influence on the experience of pain," Pain
818		Rep, vol. 2, no. 4, Jul. 2017, doi: 10.1097/PR9.000000000000000000000000000000000000
819	[69]	S. Bustan et al., "Psychological, cognitive factors and contextual influences in pain
820		and pain-related suffering as revealed by a combined qualitative and quantitative
821		assessment approach," PLoS One, vol. 13, no. 7, Jul. 2018, doi:
822		10.1371/journal.pone.0199814.
823	[70]	A. Polacchini et al., "A method for reproducible measurements of serum BDNF:
824		Comparison of the performance of six commercial assays," Sci Rep, vol. 5, Dec. 2015,
825		doi: 10.1038/srep17989.
826	[71]	S. Keen, M. Lomeli-Rodriguez, and A. C. D. C. Williams, "Exploring how people with
827		chronic pain understand their pain: A qualitative study," Scand J Pain, vol. 21, no. 4,
828		
		pp. 743-753, Oct. 2021, doi: 10.1515/sjpain-2021-0060.
829	[72]	pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060.M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications
829 830	[72]	pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060.M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications for Research and Intervention," 2008.
829 830 831	[72] [73]	 pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060. M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications for Research and Intervention," 2008. B. Lindström and M. Eriksson, "Salutogenesis," <i>Journal of Epidemiology and</i>
829 830 831 832	[72] [73]	 pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060. M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications for Research and Intervention," 2008. B. Lindström and M. Eriksson, "Salutogenesis," <i>Journal of Epidemiology and Community Health</i>, vol. 59, no. 6. pp. 440–442, Jun. 2005. doi:
 829 830 831 832 833 	[72] [73]	 pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060. M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications for Research and Intervention," 2008. B. Lindström and M. Eriksson, "Salutogenesis," <i>Journal of Epidemiology and Community Health</i>, vol. 59, no. 6. pp. 440–442, Jun. 2005. doi: 10.1136/jech.2005.034777.
 829 830 831 832 833 834 	[72] [73] [74]	 pp. 743–753, Oct. 2021, doi: 10.1515/sjpain-2021-0060. M. J. L. Sullivan, "Toward a Biopsychomotor Conceptualization of Pain Implications for Research and Intervention," 2008. B. Lindström and M. Eriksson, "Salutogenesis," <i>Journal of Epidemiology and Community Health</i>, vol. 59, no. 6. pp. 440–442, Jun. 2005. doi: 10.1136/jech.2005.034777. DP. Ausubel, "The psychology of meaningful verbal learning.," in <i>New York: Grune &</i>

T. G. K. Bryce and E. J. Blown, "Ausubel's meaningful learning re-visited," Current 836 [75] 837 Psychology, 2023, doi: 10.1007/s12144-023-04440-4. 838 [76] D. P. Ausubel, *Educational psychology: a cognitive view*. 1968. 839 A. Antonovxy, "THE STRUCTURE AND PROPERTIES OF THE SENSE OF [77] 840 COHERENCE SCALE," 1993. M. Eriksson and B. Lindström, "Antonovsky's sense of coherence scale and its 841 [78] 842 relation with quality of life: A systematic review," Journal of Epidemiology and 843 Community Health, vol. 61, no. 11. pp. 938–944, Nov. 2007. doi: 844 10.1136/jech.2006.056028. 845 P. M. Newton, A. Da Silva, and L. G. Peters, "A Pragmatic Master List of Action [79] 846 Verbs for Bloom's Taxonomy," Front Educ (Lausanne), vol. 5, Jul. 2020, doi: 847 10.3389/feduc.2020.00107. N. E. Adams, "Bloom's taxonomy of cognitive learning objectives," Journal of the 848 [80] 849 Medical Library Association, vol. 103, no. 3, pp. 152-153, 2015, doi: 10.3163/1536-5050.103.3.010. 850 851 Krathwohl DR, "From One Dimension to Two Dimensions," 2002. [81] 852 [82] K. D. Torralba and L. Doo, "Active Learning Strategies to Improve Progression from 853 Knowledge to Action," Rheumatic Disease Clinics of North America, vol. 46, no. 1. 854 W.B. Saunders, pp. 1–19, Feb. 01, 2020. doi: 10.1016/j.rdc.2019.09.001. 855 [83] J. Phillips and F. Wiesbauer, "The flipped classroom in medical education: A new standard in teaching," Trends in Anaesthesia and Critical Care, vol. 42, pp. 4-8, Feb. 856 857 2022, doi: 10.1016/j.tacc.2022.01.001. D. M. Higgins, A. M. Martin, D. G. Baker, J. J. Vasterling, and V. Risbrough, "The 858 [84] 859 relationship between chronic pain and neurocognitive function a systematic review," 860 Clinical Journal of Pain, vol. 34, no. 3. Lippincott Williams and Wilkins, pp. 262-861 275, Mar. 01, 2018. doi: 10.1097/AJP.000000000000536. H. Ebbinghaus, "Memory: A Contribution to Experimental Psychology," Ann 862 [85] Neurosci, vol. 20, no. 4, Oct. 2013, doi: 10.5214/ans.0972.7531.200408. 863 864 J. Grisart, M. Van der Linden, and C. Bastin, "The contribution of recollection and [86] 865 familiarity to recognition memory performance in chronic pain patients," Behaviour Research and Therapy, vol. 45, no. 5, pp. 1077–1084, May 2007, doi: 866 867 10.1016/j.brat.2006.05.002. 868 P. A., & G. E. J. Woźniak, "Optimization of repetition spacing in the practice of [87] 869 learning.," Acta Neurobiol Exp (Wars), pp. 54(1), 59-62., 1994.

- [88] S. Fattinger *et al.*, "Deep sleep maintains learning efficiency of the human brain," *Nat Commun*, vol. 8, May 2017, doi: 10.1038/ncomms15405.
- 872 [89] W. R. Miller and S. Rollnick, *Motivational interviewing: Preparing people to change*873 *addictive behavior.*, The Guilford Press. 1991.
- 874 [90] J. Nijs et al., "TITLE: Integrating Motivational Interviewing in Pain Neuroscience
- 875 Education for People With Chronic Pain: A Practical Guide for Clinicians RUNNING
- 876 HEAD: Motivational Interviewing Plus Explaining Pain TOC CATEGORY: Pain
- 877 Management ARTICLE TYPE: Perspective", doi: 10.1093/ptj/pzaa021/5716894.
- 878 [91] X. Bosch-Capblanch, K. Abba, M. Prictor, and P. Garner, "Contracts between patients
 879 and healthcare practitioners for improving patients' adherence to treatment, prevention
- and health promotion activities," *Cochrane Database of Systematic Reviews*, no. 2.
- 881 2007. doi: 10.1002/14651858.CD004808.pub3.
- 882 [92] F. Cuenca-Martínez, L. Suso-Martí, J. V. León-Hernández, and R. La Touche, "The
- role of movement representation techniques in the motor learning process: A
- neurophysiological hypothesis and a narrative review," *Brain Sciences*, vol. 10, no. 1.
- 885 MDPI AG, Jan. 01, 2020. doi: 10.3390/brainsci10010027.

	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation			Close-out		
Timepoint	t-1	0	t-baseline	t1 (15 days) t-postint		t3 (1 month later)	t4 (8 months later)	
ENROLMENT:								
Elegibility screen	x							
Informed consent	x							
Allocation		х						
INTERVENTIONS								
[POBTE + Exercise]			•		1			
[Exercise]			4		+			
ASSESMENTS								
Visual Analogue Scale			х	х	х	х	х	
Pressure Pain Thresholds			х	х	х	х	х	
Brain Derived Neurotrophic Factor			х	х	х	х	х	
Hospital Anxiety and Depression Scale			х	х	х	х	х	
Pain catastrophizing scale			х	х	х	х	х	
Quality of Life			х	х	х	х	х	
Chronic Pain Grading Scale			х	x	х	x	х	
Tampa Scale for Kinesiophobia			х	х	х	х	х	
Pittsburgh Sleep Quality Index			х	x	х	x	х	
Perceived Stress Scale			х	x	х	x	х	
International Physical Activity Questionnaire			х	х	х	x	х	
Knowledge questionnaire			x	x	x	X	х	
Global Perception of Change			х	x	х	x	х	
Height and Weight			x	x	x	x	х	
Sociodemographic outcomes			х	х	х	х	х	
Blood pressure			х	х	х	х	х	
Respiratory rate			х	х	х	х	х	
Saturation			х	х	х	x	x	
HR			х	Х	х	x	x	
GROC Scale							х	

Figure 1 - SPIRIT